1
|
Olsson M, Govender R, Diaz A, Holler M, Menzel A, Abrahmsén-Alami S, Sadd M, Larsson A, Matic A, Liebi M. Multiscale X-ray imaging and characterisation of pharmaceutical dosage forms. Int J Pharm 2023:123200. [PMID: 37414373 DOI: 10.1016/j.ijpharm.2023.123200] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/01/2023] [Revised: 06/30/2023] [Accepted: 07/01/2023] [Indexed: 07/08/2023]
Abstract
A correlative, multiscale imaging methodology for visualising and quantifying the morphology of solid dosage forms by combining ptychographic X-ray computed nanotomography (PXCT) and scanning small- and wide-angle X-ray scattering (S/WAXS) is presented. The methodology presents a workflow for multiscale analysis, where structures are characterised from the nanometre to millimetre regime. Here, the method is demonstrated by characterising a hot-melt extruded, partly crystalline, solid dispersion of carbamazepine in ethyl cellulose. Characterisation of the morphology and solid-state phase of the drug in solid dosage forms is central as this affects the performance of the final formulation. The 3D morphology was visualised at a resolution of 80 nm over an extended volume through PXCT, revealing an oriented structure of crystalline drug domains aligned in the direction of extrusion. Scanning S/WAXS, showed that the nanostructure is similar over the cross section of the extruded filament, with minor radial changes in domain sizes and degree of orientation. The polymorphic forms of carbamazepine were qualified with WAXS, showing a heterogeneous distribution of the metastable forms I and II. This demonstrates the methodology for multiscale structural characterization and imaging to enable a better understanding of the relationships between morphology, performance, and processing conditions of solid dosage forms.
Collapse
Affiliation(s)
- Martina Olsson
- Department of Physics, Chalmers University of Technology, SE-412 96, Gothenburg, Sweden
| | - Rydvikha Govender
- Oral Product Development, Pharmaceutical Technology and Development, Operations, AstraZeneca, SE-43183 Gothenburg, Sweden; Department of Chemistry and Chemical Engineering, Chalmers University of Technology, SE-412 96, Gothenburg, Sweden
| | - Ana Diaz
- Photon Science Division, Paul Scherrer Institut, Villigen PSI, 5232, Switzerland
| | - Mirko Holler
- Photon Science Division, Paul Scherrer Institut, Villigen PSI, 5232, Switzerland
| | - Andreas Menzel
- Photon Science Division, Paul Scherrer Institut, Villigen PSI, 5232, Switzerland
| | - Susanna Abrahmsén-Alami
- Innovation Strategies & External Liaison, Pharmaceutical Technology & Development, Operations, AstraZeneca, SE-43183 Gothenburg, Sweden
| | - Matthew Sadd
- Department of Physics, Chalmers University of Technology, SE-412 96, Gothenburg, Sweden
| | - Anette Larsson
- Department of Chemistry and Chemical Engineering, Chalmers University of Technology, SE-412 96, Gothenburg, Sweden; FibRe-Centre for Lignocellulose-based Thermoplastics, Department of Chemistry and Chemical Engineering, Chalmers University of Technology, SE-412 96 Gothenburg, Sweden
| | - Aleksandar Matic
- Department of Physics, Chalmers University of Technology, SE-412 96, Gothenburg, Sweden; FibRe-Centre for Lignocellulose-based Thermoplastics, Department of Chemistry and Chemical Engineering, Chalmers University of Technology, SE-412 96 Gothenburg, Sweden; Wallenberg Wood Science Center, Chalmers University of Technology, SE-412 96 Gothenburg, Sweden
| | - Marianne Liebi
- Department of Physics, Chalmers University of Technology, SE-412 96, Gothenburg, Sweden; Photon Science Division, Paul Scherrer Institut, Villigen PSI, 5232, Switzerland; Institute of Materials, École Polytechnique Fédérale de Lausanne (EPFL), Lausanne, 1015 Switzerland
| |
Collapse
|